Home
INVESTORS
Invest in the Future of Trauma Diagnostics
Quadplex Ultrasound™ delivers non-invasive, real-time monitoring of muscle compartments—capital-light, defensible, and globally scalable. TraumaPulse Biosystems quantifies muscular perfusion to advance safer orthopedic traumatology and beyond.
The Investment Opportunity
Market Fundamentals
Acute Compartment Syndrome (ACS) represents one of trauma care's most dangerous blind spots, with diagnostic accuracy as low as 11–15% according to AAOS Clinical Guidelines. Our AI-enabled ultrasonic platform addresses this critical unmet need.
With 170,000+ hospitals worldwide, adoption by just 200 facilities sustains a ~$1B valuation. Our software-only approach eliminates capital intensity—no probes, factories, or inventory required.
Revenue Architecture
  • SaaS hospital subscriptions: $45k–$250k annually per facility
  • OEM licensing: upfront fees plus recurring royalties
  • Research use only (RUO) applications for clinical trials
  • Expanded medical screening applications
Defensible IP portfolio includes U.S. non-provisional filing, PCT pending, and explicit Quadplex Ultrasound™ protection.
Market Drivers
Clinical Drivers
Global trauma incidence rising 8% annually (WHO Global Trauma Burden). Urgent demand for early, objective diagnostics in orthopedic traumatology and muscular perfusion assessment.
Economic Drivers
Missed ACS diagnoses fuel malpractice settlements averaging $426,000 per case, with verdicts exceeding $100M (J Bone Joint Surg, National Trauma Data Bank).
Technology Drivers
Hospitals seek AI-driven, non-invasive tools that integrate seamlessly with existing ultrasound systems (MarketsandMarkets Ultrasound Report).
Healthcare Economics
Preventing unnecessary fasciotomies saves $45,000–$80,000 per case in the U.S. and €8,500–€39,600 in the EU (EU Trauma Economics).
Strategic Positioning
Body of the Spear: TraumaPulse
Core focus on orthopedic traumatology and ACS monitoring. Quantifying muscular perfusion for safer clinical outcomes in trauma care and research applications.
Tip of the Spear: CerebroPulse
Ancillary expansion into neurology applications and ARIA drug safety monitoring, leveraging shared AI/ultrasonic platform technology.
Platform Expansion
Future applications include ICP monitoring, burn perfusion assessment, organ congestion detection, transplant viability, sepsis perfusion monitoring, and obstetrics.
Exit Pathways
Strategic acquisition by OEM partners (GE Healthcare, Philips, Siemens Healthineers) or public offering as regulatory approvals advance beyond RUO designation.
Regulatory Positioning
TraumaPulse Biosystems provides AI/ultrasonic-enabled muscular perfusion data for orthopedic traumatology trials (RUO), broader healthcare research, and medical screening purposes. Our platform is positioned for strategic regulatory advancement.
Why Invest in TraumaPulse
Clinical Impact
Prevents amputations, reduces malpractice risk, and saves lives through accurate muscular perfusion quantification. Gold standard potential in trauma diagnostics.
Capital Efficiency
SaaS plus OEM licensing model keeps burn low and margins high. Software-only platform eliminates manufacturing overhead and inventory complexity.
Defensible IP
Quadplex Ultrasound™ patent estate creates durable barriers to entry. U.S. non-provisional filed with PCT pending provides global protection.
Global Vision
Scalable platform across trauma, neurology, and broader healthcare innovation. 170,000+ hospitals worldwide represent massive addressable market.
Team Credibility
Leadership with proven medtech exits, regulatory expertise, and scientific depth. Collaboration with CerebroPulse Biosystems expands strategic capabilities.
Market Position
First-mover advantage in muscular perfusion quantification for orthopedic traumatology. Positioned to become gold standard across multiple specialties.
TraumaPulse Biosystems is positioned to become the gold standard in trauma diagnostics and a platform for multi-specialty expansion.
Join Us in Making the Invisible Visible
01
Review Investment Materials
Access our comprehensive investor package with detailed market analysis, financial projections, and regulatory roadmap.
02
Meet Our Team
Connect with leadership to discuss clinical validation, IP strategy, and commercial execution plans.
03
Partner for Impact
Join us in transforming trauma care through innovative muscular perfusion quantification technology.
Investment Thesis
Invest in Quadplex Ultrasound™—a breakthrough that combines measurable medical impact with billion-dollar commercial potential. Our AI/ultrasonic platform quantifies muscular perfusion to advance safer orthopedic traumatology and transform healthcare research.
TraumaPulse Biosystems offers accredited investors a unique opportunity to participate in regulatory-compliant innovation that addresses critical unmet needs in trauma diagnostics while building a scalable, defensible platform.